Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
san francisco blog main
biotech
fda
new york top stories
roche
san francisco top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
amgen
andrew oxtoby
babies
boston
boulder/denver blog main
boulder/denver top stories
breakup
bridge bio pharma
cancer
cancer immunotherapy
center for medicare and medicaid services
ceo
cholesterol
clinical hold
clinical study
clinical trials
combination
commissioner
companion diagnostic
congress
crispr
crispr-cas9
daniel o'day
data
What
big
3
×
medicine
3
×
ceo
week
aces
acquire
agreed
announced
billion
bio
bosley's
bosley’s
bridge
broad
bucks
cas
cholesterol
confidence
crime
crispr
departure
didn’t
drug
editas
exit
flexible
foundation
gain
genentech
guiding
inclisiran
katrine
key
lowering
meant
medco
medicines
momentum
morning
moves
Language
unset
Current search:
big
×
medicine
×
" boston blog main "
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
